About Vium
Vium is a Healthcare company based in San Mateo (United States) founded in 2013, and was acquired by Recursion in July 2020. Provider of living informatics platform for preclinical in vivo drug research. Vium has raised $86 million across 7 funding rounds from investors including Recursion Pharmaceuticals, Lux Capital and DCVC. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Scientific Sourcing. Its competitors include Scientist.com, Scrazzl and AllSeq; 1 of its 3 listed competitors has raised funding.
Company details
Vium (under the stealth name Mousera) has developed a living informatics platform for preclinical in vivo drug research. Its products The Vium Digital Vivarium, Vium Cloud, and online Research Suite aids scientists with bioengineered research models and serves the customers in the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies, academia and novel therapeutic labs. It also develops best-in-class animal models with automated, digital efficacy and health metrics across a variety of therapeutic areas such as RA, MS, Lupus, Health Span aging biology.
- Total Equity Funding$86M (USD)
in 7 rounds
- Latest Funding Round$24M (USD), Series B
Jun 2018
- InvestorsRecursion Pharmaceuticals
& 6 more
- Acquired byRecursion
(Jul 2020)
Funding Insights of Vium
Vium has successfully raised a total of $86M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $86M
- Total Rounds 7
- Last Round Series B — $24M
- First Round $1.2M
(Jun 2014)
- Investors Count 6
All 7 funding rounds of Vium with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $24M | Series B | – | Lux Capital, DCVC | |
| Nov 2017 | $3.1M | Series B | – | – | – |
| Jun 2015 | $20M | Series B | – | – | |
| Jun 2015 | $20M | Series B | – | DCVC | |
| Oct 2014 | $8.85M | Series A | – | – | – |
| Oct 2014 | $8.85M | Series A | – | – | – |
| Jun 2014 | $1.2M | Seed | – | – | – |
7 investors in total: 7 institutional.
Investors in Vium
Vium has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Lux Capital and DCVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors | dolbyventures.com | San Francisco, United States | ||
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
FutureShape is involved in shaping and building futures. | futureshape.com | Paris, France | ||
AME Cloud Ventures is focused on investing in data-driven technology companies. | amecloudventures.com | Palo Alto, United States | ||
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | recursion.com | New York, United States |
Investor details for Vium
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vium
7 people are tracked at Vium (7 in board & advisors).
| Name | Role | Group |
|---|---|---|
Annalisa Jenkins | Board Member | Board & advisors |
Scott J. Dylla | Advisor | Board & advisors |
David Sinclair | Advisor | Board & advisors |
Peter Hebert | Board Member | Board & advisors |
Clifford Roberts | Advisor | Board & advisors |
Jeff Kindler | Board Member | Board & advisors |
Zachary Bogue | Board Member | Board & advisors |
Complete people profiles for Vium
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vium
4 dated milestones of Vium across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Vium is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Series B, of $24.0M.
- Exit Acquired by Recursion.
Competitors of Vium
Vium has 3 listed competitors in our database, 1 of them funded. They include Scientist.com, Scrazzl and AllSeq.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scientist.com | 2007 | Solana Beach, United States | $43.89M | 20 | Online marketplace for preclinical drug development services is operated. | |
| scrazzl.com | 2010 | San Francisco, United States | Search and research tool | |||
| allseq.com | 2013 | San Diego, United States | Operates an online marketplace for DNA sequencing services. |
Detailed competitors of Vium
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vium
Websites that share an audience with Vium (vium.com).
Websites whose visitors overlap most with Vium. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| youtube.com | 100% | 30.4B | #2 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Vium (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vium
Complete news archive for Vium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vium
Vium was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Vium is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Vium is a funded company, having raised a total of $86M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.2M, raised on Jun 2014.
Vium (under the stealth name Mousera) has developed a living informatics platform for preclinical in vivo drug research. Its products The Vium Digital Vivarium, Vium Cloud, and online Research Suite aids scientists with bioengineered research models and serves the customers in the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies, academia and novel therapeutic labs. It also develops best-in-class animal models with automated, digital efficacy and health metrics across a variety of therapeutic areas such as RA, MS, Lupus, Health Span aging biology.
Vium's top competitors include Scientist.com, Scrazzl and AllSeq.
Vium has 7 investors. Key investors include Recursion Pharmaceuticals, Lux Capital, DCVC, Dolby Family Ventures, and Founders Fund.
Yes. Vium was acquired by Recursion in July 2020.